Climb Bio, Inc. (CLYM)

NASDAQ · Pharmaceuticals & Biotech · Pharmaceutical Preparations

Price
$11.89
Day
-5.03%
Market cap
$682.92M

Close 2026-09-24.

The company

Company Overview We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the potential to address multiple indications. We are developing our product candidates for multiple immune-mediated diseases, as summarized in the pipeline figure below. We acquired the rights to our product candidates through license and asset purchase agreements. We have worldwide rights to develop and commercialize budoprutug for all indications, except for oncology. We have rights to develop and commercialize CLYM116 for all indications worldwide outside of mainland China, Hong Kong, Macau, and Taiwan, which we refer to as Greater China.

From Item 1: Company Overview.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

Recent filings